Cardiomyopathies in Noonan syndrome and the other RASopathies

Progress in Pediatric Cardiology

Volumn 39, Issue 1, 2015, Pages 13-19

  Gelb, Bruce D ^a,c   Roberts, Amy E ^a   Tartaglia, Marco ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Dilated cardiomyopathy; Hypertrophic cardiomyopathy; RAS MAP kinase signal transduction; RASopathies

Indexed keywords

BINIMETINIB; EVEROLIMUS; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SOS PROTEIN; TUBERIN;

ASTROCYTOMA; BLOOD PROTEIN DISORDER; CARDIOFACIOCUTANEOUS SYNDROME; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; COSTELLO SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG SAFETY; ENZYME ACTIVATION; GENE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HRAS GENE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTRACELLULAR SIGNALING; NONHUMAN; NOONAN SYNDROME; NRAS GENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PTPN11 GENE; RAF1 GENE; RASOPATHY; REVIEW; SOS1 GENE; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

EID: 84938555313     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2015.01.002     Document Type: Review

References (39)

1. Roberts A.E., Allanson J.E., Tartaglia M., Gelb B.D. Noonan syndrome. Lancet 2013, 381:333-342.
2. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
3. Burch M., Mann J.M., Sharland M., Shinebourne E.A., Patton M.A., McKenna W.J. Myocardial disarray in Noonan syndrome. Br Heart J 1992, 68:586-588.
4. Hickey E.J., Mehta R., Elmi M., et al. Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis 2011, 6:41-47.
5. Wilkinson J.D., Lowe A.M., Salbert B.A., et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012, 164:442-448.
6. Shaw A.C., Kalidas K., Crosby A.H., Jeffery S., Patton M.A. The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 2007, 92:128-132.
7. Limongelli G., Pacileo G., Marino B., et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 2007, 100:736-741.
8. Lin A.E., Alexander M.E., Colan S.D., et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A 2011, 155A:486-507.
9. Tomita H., Fuse S., Ikeda K., Matsuda K., Chiba S. An infant with Costello syndrome complicated with fatal hypertrophic obstructive cardiomyopathy. Acta Paediatr Jpn 1998, 40:608-611.
10. Roberts A., Allanson J., Jadico S.K., et al. The cardiofaciocutaneous syndrome. J Med Genet 2006, 43:833-842.
11. Mazzanti L., Cacciari E., Cicognani A., Bergamaschi R., Scarano E., Forabosco A. Noonan-like syndrome with loose anagen hair: a new syndrome?. Am J Med Genet A 2003, 118A:279-286.
12. Gripp K.W., Zand D.J., Demmer L., et al. Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: structural brain anomalies and myelofibrosis. Am J Med Genet A 2013, 161:2420-2430.
13. Komatsuzaki S., Aoki Y., Niihori T., et al. Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies. J Hum Genet 2010, 55:801-809.
14. Mazzanti L., Tamburrino F., Scarano E., et al. GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome). Am J Med Genet A 2013, 161A:2756-2761.
15. Cordeddu V., Di Schiavi E., Pennacchio L.A., et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 2009, 41:1022-1026.
16. Tartaglia M., Mehler E.L., Goldberg R., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001, 29:465-468.
17. Fragale A., Tartaglia M., Wu J., Gelb B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004, 23:267-277.
18. Tartaglia M., Gelb B.D. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 2010, 1214:99-121.
19. Digilio M.C., Conti E., Sarkozy A., et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002, 71:389-394.
20. Legius E., Schrander-Stumpel C., Schollen E., Pulles-Heintzberger C., Gewillig M., Fryns J.P. PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002, 39:571-574.
21. Tartaglia M., Martinelli S., Stella L., et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006, 78:279-290.
22. Kontaridis M.I., Swanson K.D., David F.S., Barford D., Neel B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006, 281:6785-6792.
23. Hanna N., Montagner A., Lee W.H., et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 2006, 580:2477-2482.
24. Aoki Y., Niihori T., Kawame H., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005, 37:1038-1040.
25. Tartaglia M., Kalidas K., Shaw A., et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002, 70:1555-1563.
26. Lepri F., De Luca A., Stella L., et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat 2011, 32:760-772.
27. Pandit B., Sarkozy A., Pennacchio L.A., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007, 39:1007-1012.
28. Razzaque M.A., Nishizawa T., Komoike Y., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007, 39:1013-1017.
29. Aoki Y., Niihori T., Banjo T., et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 2013, 93:173-180.
30. Gripp K.W., Hopkins E., Sol-Church K., et al. Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. Am J Med Genet A 2011, 155A:706-716.
31. Allanson J.E., Anneren G., Aoki Y., et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype?. Am J Med Genet C Semin Med Genet 2011, 157C:129-135.
32. Abe Y., Aoki Y., Kuriyama S., et al. Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey. Am J Med Genet A 2012, 158A:1083-1094.
33. Wu X., Simpson J., Hong J.H., et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 2011, 121:1009-1025.
34. Chen P.C., Wakimoto H., Conner D., et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 2010, 120:4353-4365.
35. Marin T.M., Keith K., Davies B., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 2011, 121:1026-1043.
36. Edouard T., Combier J.P., Nedelec A., et al. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol Cell Biol 2010, 30:2498-2507.
37. Schuhmacher A.J., Guerra C., Sauzeau V., Canamero M., Bustelo X.R., Barbacid M. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 2008, 118:2169-2179.
38. Dhandapany P.S., Razzaque M.A., Muthusami U., et al. RAF1 mutations in childhood-onset dilated cardiomyopathy. Nat Genet 2014, 46:635-639.
39. Lee Y.S., Ehninger D., Zhou M., et al. Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. Nat Neurosci 2014, 17:1736-1743.